D.A. Davidson & Co’s Nektar Therapeutics NKTR Stock Holding History

D.A. Davidson & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-307	Closed	-$280K	–	1145
2018 Q3	$280K	Hold	307	–	–	0.01%	940
2018 Q2	$225K	Hold	307	–	–	﹤0.01%	987
2018 Q1	$489K	Hold	307	–	–	0.01%	695
2017 Q4	$275K	Buy	+307	New	+$182K	0.01%	882
2017 Q3	–	Sell	-307	Closed	-$89K	–	1682
2017 Q2	$89K	Hold	307	–	–	﹤0.01%	1313
2017 Q1	$107K	Sell	307 -66	-18%	-$14.8K	﹤0.01%	1219
2016 Q4	$68K	Hold	373	–	–	﹤0.01%	1471
2016 Q3	$96K	Sell	373 -34	-8%	-$8.75K	﹤0.01%	1242
2016 Q2	$86K	Buy	407 +374	+1,133%	+$83.6K	﹤0.01%	1183
2016 Q1	$6K	Hold	33	–	–	﹤0.01%	2010
2015 Q4	$8K	Buy	+33	New	+$6.79K	﹤0.01%	1940

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.A. Davidson & Co's NKTR Position: Q4 2018 in Review

D.A. Davidson & Co sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 307 shares — an estimated $280K sold.

D.A. Davidson & Co first reported a position in NKTR in Q4 2015 and held it in 11 quarters. The position peaked at $489K in Q1 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

D.A. Davidson & Co reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
D.A. Davidson & Co sold 307 Nektar Therapeutics shares in Q4 2018, an estimated $280K.
D.A. Davidson & Co first reported a position in Nektar Therapeutics in Q4 2015 and held it in 11 quarters.
D.A. Davidson & Co's Nektar Therapeutics position peaked at $489K in Q1 2018.
342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on D.A. Davidson & Co's 13F filing for Q4 2018, filed 29 Jan 2019.